|Bid||6.20 x 0|
|Ask||6.21 x 0|
|Day's Range||6.06 - 6.28|
|52 Week Range||6.06 - 74.28|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 12, 2020 - Nov. 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.72|
Aurora Cannabis (NYSE: ACB) is a shadow of its former self. It's no longer the leader in the Canadian adult-use recreational cannabis market, and its hopes of landing a major partner from outside the cannabis industry have fizzled. For most of the last five years, Aurora ranked behind only Canopy Growth (NYSE: CGC) among Canadian cannabis producers based on market cap.
Over the past 18 months, the North American marijuana industry has struggled, and a number of popular pot stocks have been pulverized. Every next-big-thing investment contends with growing pains, and that's exactly what marijuana stocks are navigating their way through at the moment. To our north, Canada has been punished by a plethora of regulatory-based supply issues.
If you had invested $10,000 in Aurora Cannabis (NYSE: ACB) just a year ago, your initial investment would be worth a meager $851 as of Sep. 29. Canada's nationwide legalization of marijuana in Oct. 2018 was supposed to bring sweeping success to the country's pot companies. Not only did Aurora get its market dynamics wrong, but management of its existing capital will probably cause more woes for investors in the future.